{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:38:32Z","timestamp":1772793512270,"version":"3.50.1"},"reference-count":15,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The worldwide increase in fluoroquinolone-resistant and extended-spectrum \u03b2-lactamase (ESBL)-producing\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            pathogens has led to doripenem and other carbapenems assuming a greater role in the treatment of serious infections. We analyzed data from 6 phase 3 multinational doripenem clinical trials on ciprofloxacin-resistant\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            isolates consisting of all genera (CIPRE) and ESBL-producing\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            isolates consisting of\n            <jats:italic>Escherichia coli<\/jats:italic>\n            ,\n            <jats:italic>Klebsiella<\/jats:italic>\n            spp., and\n            <jats:italic>Proteus<\/jats:italic>\n            spp. with ceftazidime MICs of \u22652 \u03bcg\/ml (ESBLE) for prevalence by geographic region and disease type,\n            <jats:italic>in vitro<\/jats:italic>\n            activities of doripenem and comparator agents, and clinical or microbiologic outcomes in doripenem- and comparator-treated patients across disease types (complicated intra-abdominal infection [cIAI], complicated urinary tract infection [cUTI], and nosocomial pneumonia [NP]). Of 1,830 baseline\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            isolates, 88 (4.8%) were ESBLE and 238 (13.0%) were CIPRE. The incidence of ESBLE was greatest in Europe (7.8%); that of CIPRE was higher in South America (15.9%) and Europe (14.4%). ESBLE incidence was highest in NP (12.9%) cases; that of CIPRE was higher in cUTI (18.3%) and NP (14.9%) cases. Against ESBLE and CIPRE, carbapenems appeared more active than other antibiotic classes. Among carbapenems, doripenem and meropenem were most potent. Doripenem had low MIC\n            <jats:sub>90<\/jats:sub>\n            s for CIPRE (0.5 \u03bcg\/ml) and ESBLE (0.25 \u03bcg\/ml). Doripenem and comparators were highly clinically effective in infections caused by\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            , irrespective of their ESBL statuses. The overall cure rates were the same for doripenem (82%; 564\/685) and the comparators (82%; 535\/652) and similar for ESBLE (73% [16\/22] versus 72% [21\/29]) and CIPRE (68% [47\/69] versus 52% [33\/64]). These findings indicate that doripenem is an important therapeutic option for treating serious infections caused by ESBLE and CIPRE.\n          <\/jats:p>","DOI":"10.1128\/aac.01450-09","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T05:29:47Z","timestamp":1268112587000},"page":"2119-2124","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":31,"title":["Worldwide Experience with the Use of Doripenem against Extended-Spectrum-\u03b2-Lactamase-Producing and Ciprofloxacin-Resistant\n            <i>Enterobacteriaceae<\/i>\n            : Analysis of Six Phase 3 Clinical Studies"],"prefix":"10.1128","volume":"54","author":[{"given":"Kone\u0301","family":"Kaniga","sequence":"first","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Flamm","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Yir","family":"Tong","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lee","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Friedland","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Redman","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181691b99"},{"key":"e_1_3_2_3_2","unstructured":"Performance standards for antimicrobial susceptibility testing; 16th informational supplement 19087-1898 2006"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02101.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868140-00007"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.04.019"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.02.002"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00837-08"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-008-0656-6"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.1.23"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00381-08"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.5.657"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki166"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802179255"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767070-00006"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01450-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01450-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:24:32Z","timestamp":1645475072000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01450-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1128\/AAC.01450-09"],"URL":"https:\/\/doi.org\/10.1128\/aac.01450-09","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"2009-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-02-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}